Datametrex Chairman Announces Private Share Sale to Position Sophisticated High Net Worth Investor

Datametrex AI Limited

TORONTO, July 26, 2020 (GLOBE NEWSWIRE) -- Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) announced today that Andrew Ryu, Chairman of the Company, has facilitated a block trade of 9.3M Common Shares (the “Shares”) to a high net worth sophisticated investor who after doing due diligence on the Company wanted to acquire a significant position.

Mr. Ryu recently exercised 7.5M options and warrants in order to facilitate the trade and not dilute his share position. 

“The timing for this trade to happen was perfect, I was sitting on millions of options and warrants, many of which were soon to expire. By entering into this trade, I was able to capitalize Datametrex by exercising my warrants and options and position sophisticated high net worth investor with a significant position” says Andrew Ryu, Chairman of the Company. “Aside from keeping some funds aside for tax purposes, I was able to maintain my position and strengthen the balance sheet and shareholder base”    

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy ( Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300

Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

More From

  • RespireRx Pharmaceuticals Inc. Announces Extension to Long-Term Employment Contract with Tim Jones as President and Chief Executive Officer

    Glen Rock, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”), is pleased to announce that today, Mr. Tim Jones and RespireRx have transitioned from the provisional period that commenced on May 6, 2020 to the three year, long-term portion of the employment contract with Mr. Jones as its President and Chief Executive Officer. Mr. Jones has been a member of the Company’s Board of Directors since January 28, 2020 and as of July 31st. 2020, successfully completed the 3-month contractual provisional period. RespireRx is a leader in the development of innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling, which affect millions of people, but for which there are limited or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”) and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases such as Fragile X Syndrome. On August 1, 2020, RespireRx has formally entered into the three-year phase of the employment contract with Tim Jones serving as its President and Chief Executive Officer (“CEO”). The original employment contract had an initial provisional term of approximately 3 months, through July 31, 2020. The employment contract having not been terminated by either party during the provisional term automatically extended into the long-term portion. The Board has acknowledged that it wishes the term of the employment contract to extend beyond the Provisional Period and Mr. Jones has acknowledged the same. The contract will expire on September 30, 2023 unless earlier terminated in accordance with the terms of the employment contract. The Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice of its intention not to extend the term of the Agreement at least ninety (90) days prior to the applicable Renewal Date. As previously disclosed in the Company’s Current Report on Form 8-K filed February 3, 2020, Mr. Jones joined the Company’s board of directors on January 28, 2020.Mr. Jones stated that “this transition into the long-term portion of my employment contract with RespireRx is an expression of my belief in the value of the assets, the synergies of working with the other members of the management team and my confidence that I will continue to be a contributing senior member of that team that intends to add to and then realize the value of the Company for the benefit of all stakeholders.”Dr. Lippa, Executive Chairman and Chief Scientific Officer said, “I am thrilled that both Tim and the Board are in complete agreement about the transition from the provisional period to the long-term phase of Tim’s employment contract and, speaking for the Board and the rest of the management team, we are excited to continue working in partnership with him going forward.”Mr. Jones is a highly experienced senior executive with a proven and outstanding track record in global commercial business development, specializing in developing and sustaining high value strategic and tactical partnerships. He is recognized for his expertise in the strategic development and growth of active pharmaceutical ingredient categories through partnerships with a broad cross section of brand and generic pharmaceutical and biopharmaceutical companies worldwide. His extensive knowledge base and expertise across multiple pharmaceutical disciplines have contributed to his successful track record of financial growth. For the past three years, as Vice President of Global Pharmaceutical and Medical OTC at Purisys LLC, an affiliate of Noramco Inc., and as Vice President Business Development-Global Cannabinoids Portfolio at Noramco Inc., Mr. Jones was instrumental in building a fully operational and highly successful global commercial cannabinoids business. Prior to that, he was Vice President Strategic Portfolio Management at Midas Pharmaceuticals Inc. and also has previously held leadership roles with Par Sterile Products, and Johnson Matthey.About RespireRx Pharmaceuticals Inc.RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders and central nervous system (“CNS”) indications, with a focus on OSA, ADHD, SCI and other neurological conditions. The Company owns and has exclusive rights to patents and patent applications for certain families of chemical compounds that claim the chemical structures, formulations and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.RespireRx is developing a pipeline of new drug products based on our broad patent portfolios across two distinct drug platforms:Pharmaceutical Cannabinoids, including dronabinol, a synthetic version of ∆-9-tetrahydrocannabinol (“∆-9-THC”), a naturally occurring substance in the cannabis plant that acts upon the nervous system’s endogenous cannabinoid receptors.RespireRx is developing dronabinol for the treatment of OSA, a serious respiratory disorder that impacts an estimated 29.4 million people in the United States according to the American Academy of Sleep Medicine. OSA has been linked to increased risk for hypertension, heart failure, depression, and diabetes, and has an annual economic cost in the United States of $162 billion according to the AASM. There are no approved drug treatments for OSA.Pending the completion of a new formulation of dronabinol and an intended pre-IND meeting with the FDA, RespireRx believes that it will be able to commence a pharmacokinetic study for the new formulation followed by a Phase 3 clinical study for the treatment of OSA. Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, the Company further believes that its re-purposing strategy would only require approval by the FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway that allows the use of publicly available data. Neuromodulators, which we now call Project Endeavor, including (a) ampakines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function and (b) positive allosteric modulators (“PAMs”) of the gamma-amino-butyric acid type A (“GABAA”) receptors that are the subject of an option agreement dated March 2, 2020 between the Company and the UWM Research Foundation, Inc. (“UWMRF”), an affiliate of the University of Wisconsin-Milwaukee.Several ampakines, in both oral and injectable forms, are being developed by the Company for the treatment of a variety of CNS disorders. In clinical studies of respiratory function, select ampakines have shown preliminary efficacy in central sleep apnea and in the control of respiratory depression produced by opioids, without altering the opioid analgesic effects. In animal models of certain orphan disorders, such as Pompe Disease, Rett’s Syndrome and perinatal respiratory distress, certain ampakines have been shown to improve breathing function. Although the Company does not intend to pursue respiratory indications for ampakines at the present time, we view these findings as proof of target engagement and signals of clinical efficacy.Ampakines have shown potential as possible therapeutic agents for the treatment of certain neuropsychiatric and neurological disorders. Ampakines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adults with ADHD. At present, the major pharmacotherapies available for ADHD are made up of two types of drugs. Stimulants, such as amphetamine, rapidly produce robust effects, but suffer from side effects typical of stimulants, including tolerance, dependence, withdrawal and abuse. For these reasons, stimulants are scheduled by the FDA. Non-stimulants, such as Strattera® (atomoxetine) tend to be less effective than stimulants, with a much longer (approximately 4 – 8 week) latency to onset of action. In a number of animal and human studies, CX717 and other ampakines did not display any stimulant properties typically associated with drugs like amphetamine. In the Phase 2 ADHD clinical trial, statistically significant therapeutic effects were observed within one week. Therefore, we believe ampakines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulant treatment options.RespireRx owns certain composition of matter and use patents and patent applications with respect to ampakines CX1739, CX717 and other ampakines.The lead compound in the GABAA PAM program has shown strong activity in a large number of animal models of epilepsy, including treatment refractory epilepsy, where there exists a great clinical need. Furthermore, it has reduced epileptogenic electrical activity in brain slices from treatment resistant epilepsy patients who had undergone surgical removal of the tissue. This lead compound also has shown activity in animal models of anxiety and neuropathic pain.Additional information about the Company and the matters discussed herein can be obtained on the Company’s web-site at or in the Company’s filings with the Securities and Exchange Commission at Note Regarding Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Company intends that such forward-looking statements be subject to the safe harbor created thereby. These might include statements regarding the Company’s future plans, targets, estimates, assumptions, financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about research and development efforts, including, but not limited to, preclinical and clinical research design, execution, timing, costs and results, future product demand, supply, manufacturing, costs, marketing and pricing factors. In some cases, forward-looking statements may be identified by words including “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “contemplates,” “targets,” “continues,” “budgets,” “may,” and similar expressions and such statements may include, but are not limited to, statements regarding (i) future research plans, expenditures and results, (ii) potential collaborative arrangements, (iii) the potential utility of the Company’s proposed products, (iv) reorganization plans, and (v) the need for, and availability of, additional financing. The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties. These forward-looking statements are based on assumptions regarding the Company’s business and technology, which involve judgments with respect to, among other things, future scientific, economic, regulatory and competitive conditions, collaborations with third parties, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, actual results may differ materially from those set forth in the forward- looking statements. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the Company’s objectives or plans will be achieved. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available cash, research and development results, competition from other similar businesses, interest of third parties in collaborations with us, and market and general economic factors. For more information about the risks and uncertainties the Company faces, see “Item 1A. Risk Factors” of the RespireRx Pharmaceuticals Inc. Annual Report on Form 10-K as of December 31, 2019. Forward-looking statements speak only as of the date they are made. The Company does not undertake and specifically declines any obligation to update any forward-obligation to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.Company Contact:Jeff Margolis Senior Vice President, Chief Financial Officer, Treasurer and Secretary Telephone: (917) 834-7206 E-mail: jmargolis@respirerx.comRespireRx Pharmaceuticals, Inc. 126 Valley Road, Suite C, Glen Rock, NJ 07452

  • Associa Chicagoland and Associa Arizona Offer Virtual Event Series to Clients

    Chicago, IL, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Associa Chicagoland and Associa Arizona recently partnered to host a series of virtual events to engage their clients and provide an outlet for continued health and wellness. The first event, a yoga webinar led by Carrie Temkin, walked through a sequence of yoga poses that taught participants to embrace a sense of calm amidst the feeling of stress, anxiety, and tiredness. Ms. Temkin is a certified yoga instructor with over eight years of experience at Total Body Yoga. During the virtual session, she instructed participants in using breath and movement to explore balance, building strength, and gaining flexibility. The second webinar event was a dinner and dessert cooking demo with Marti Sullivan from Sweet Basil Gourmetware & Cooking School and chef Terri Milligan from Chef Milligan’s Culinary classroom. Together, the culinary professionals demonstrated how to prepare an entrée of balsamic maple-glazed salmon with jeweled Moroccan couscous, followed by a key lime mousse parfait for dessert. Ms. Sullivan opened Sweet Basil Gourmetware & Cooking School in 1993, specializing in hands-on cooking classes. In addition, the business is open for lunch through the Sweet Basil Market Café and sells over 9,000 different culinary products, merchandise, and gifts. Ms. Milligan’s wide-ranging culinary career has included owning a catering firm and The Inn at Kristofer’s, working as a cooking class instructor and food writer, heading her culinary YouTube channel, and getting featured on the Food Network and Wisconsin Public Radio. “Associa Chicagoland knows that as the COVID-19 health crisis continues, communities are looking for unique ways to safely connect while engaging in new and exciting opportunities,” stated Stephanie Skelley, Associa Chicagoland president.  “By partnering with the Associa Arizona team, we were able to offer our clients a chance to engage in a fun, creative outlet with participants from across the U.S. Events like these help people fight feelings of isolation and embrace a sense of community.”With more than 200 branch offices across North America, Associa delivers unsurpassed management and lifestyle services to nearly five million residents worldwide. Our 10,000+ team members lead the industry with unrivaled education, expertise and trailblazing innovation. For more than 40 years, Associa has provided solutions designed to help communities achieve their vision. To learn more, visit us on Facebook: Subscribe to the Blog: us on Twitter: us on LinkedIn: * Associa Arizona CONTACT: Ashley Cantwell Associa 214-272-4107

  • HER2 Amplification Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

    Summary HER2 Amplification Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.New York, Aug. 03, 2020 (GLOBE NEWSWIRE) -- announces the release of the report "HER2 Amplification Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)" - The model discusses in detail the impact of COVID-19 on HER2 Amplification Tests market for the year 2020 and beyond.Breast cancer is the most frequent cancer in women and is now the leading cause of female cancer-related deaths worldwide. Approximately 18 million new breast cancer cases were reported in 2018, with approximately 2.1 million newly diagnosed cases, accounting for almost 1 in 4 cancer cases among women. Human epidermal growth factor receptor 2 (HER2 Amplification) is a transmembrane tyrosine kinase receptor belonging to the family of epidermal growth factor receptors (EGFRs). The protein is encoded by the HER2 Amplification (ERBB2) gene, which is located on the long arm of chromosome 17 (17q12-21.32). The inappropriate activation of HER2 Amplification is associated with the development of several malignancies, including breast, gastric, ovarian, colorectal, pancreatic, and endometrial cancers. An accurate evaluation of HER2 Amplification status is crucial for identification of patients who would most likely benefit from targeted anti-HER2 Amplification therapies. In breast cancer, HER2 Amplification gene amplification, occurs in 18% to 20% of patients. On the other hand, the reported HER2 Amplification positivity in patients with gastric cancer ranges widely from 10% to 30% depending on the histologic subtype and location. Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes.To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data. Key Inclusions of the market model are - Currently marketed HER2 Amplification Tests and evolving competitive landscape - \- Insightful review of the key industry trends. \- Annualized total HER2 Amplification Tests market revenue by segment and market outlooks from 2015-2030. \- Granular data on total procedures, units, average selling prices and market values by segment. Global, Regional and Country level market specific insights - \- Qualitative market specific information is available with global trends further broken down into regional trends. In addition analysts provide unique country specific insights on the market. \- SWOT analysis for HER2 Amplification Tests market. \- Competitive dynamics insights and trends provided for HER2 Amplification Tests market. Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape. \- Country specific overview of the healthcare system. \- Country specific reimbursement policies. \- Country specific medtech regulatory landscape. Robust methodologies and sources enable the model to provide extensive and accurate overview of the market.Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases. Companies covered: F. Hoffmann-La Roche Ltd , Abbott Laboratories , Agilent Technologies Inc , Leica Microsystems , Medac Diagnostics and Others Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile. Scope This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for - \- CMO executives who must have deep understanding of the HER2 Amplification Tests market place to make strategic planning and investment decisions. \- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. \- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets. Reasons to Buy The model will enable you to - \- Understand the impact of COVID-19 on HER2 Amplification Tests market. \- Develop and design you’re in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. \- Develop business strategies by understanding the trends shaping and driving HER2 Amplification Tests market. \- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HER2 Amplification Tests market in the future. \- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders. \- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. \- Track device sales in the global and country-specific HER2 Amplification Tests market from 2015-2030. \- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001

  • Announcing the Launch of the Sight Tech Global event

    A global, virtual event focused on how rapid advances in AI-related technologies will alter the future of accessibility and assistive technologies Sponsored by Verizon Media and Live-streamed on TechCrunch, December 2-3, 2020NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Today, Sight Tech Global announced its first annual event, dedicated to rapidly advancing technologies and innovations for people who are blind or visually impaired. The first of its kind, virtual and global event will livestream on Verizon Media’s TechCrunch on December 2-3 and also be available live and on-demand on other platforms. Sight Tech Global will convene top technologists, human-computer interaction specialists, product designers, researchers, entrepreneurs and advocates to discuss the future of assistive technology as well as accessibility in general and how powerful emerging technologies like AI and AR will alter current-day approaches to navigation, human interaction, and access to information. Many of those experts and technologists will themselves be blind or visually impaired.  “It’s very exciting to draw on TechCrunch’s expertise in events production to assemble the world’s top experts on the topic of accessibility and rapidly advancing technologies like AI," says Ned Desmond, Sight Tech Global’s founder and the former COO at TechCrunch. “Everyone working in this area believes we are on the cusp of a revolution in capabilities and at the same time there’s a huge amount of work to apply these emerging technologies in smart, inclusive and affordable ways.”The Sight Tech Global website launched today and is open to the public. Sign up today to receive a free pass to the event, which will be 100% virtual. A $25 Pro Pass option will also be available that offers a more in-depth experience, including breakout sessions, Q&A with speakers, and networking. To sign up and learn more go to Initial sponsors for the event include Verizon Media, Waymo and TechCrunch. Sight Tech Global is also announcing three speakers on the agenda: Professor Amnon Shashua, SVP at Intel, Dr. Cecily Morrison, a principal researcher at Microsoft, and Jim Fruchterman, founder of Benetech.Sight Global Tech is the initiative of the Vista Center for the Blind and Visually Impaired, a non-profit serving people with sight loss  in Silicon Valley and the surrounding area. All proceeds from Sight Tech Global will go to the Vista Center. "Sight Tech Global is a natural initiative for Vista Center, given our location in Silicon Valley, which has been the source of so much technology to benefit people who are blind or visually impaired, " says John Glass, the Vista Center board treasurer, who was born blind and worked for decades in sales and quality assurance roles at tech firms. "Our hope is that this event helps quicken the effort to bring the latest technologies to bear on accessibility." This year marks the 30th anniversary of the signing of the Americans with Disabilities Act of 1990, which is a reminder to all technology and media companies of the work that remains to be done to make their products fully accessible.Verizon Media’s support for the event underscores the company’s commitment to creating premium experiences for all of its users - including the 253 million people in the world who live with some type of visual impairment.  "Sight Tech Global's focus on the application of advanced technologies like AI for assuring full inclusion of people with disabilities in our society is one of the most important discussions we should have right now," said Larry Goldberg, Verizon Media's Head of Accessibility. Verizon Media is providing advice on available resources for assuring a fully accessible event.Sight Tech Global is a virtual, global event founded in 2020 dedicated to exploring  how advances in technologies like AI will produce better assistive technology and accessibility for people who are blind or visually impaired. The event is an initiative of the Vista Center for the Blind and Visually Impaired.Vista Center for the Blind and Visually Impaired The Vista Center, a 501 (c) (3) non-profit serves thousands of youth, working adults and seniors, who are blind or visually impaired through evaluation, counseling, education and training in Silicon Valley and the surrounding area. Founded in 1936, Vista Center is committed to developing thought leadership through the establishment of Sight Tech Global.Verizon Media Verizon Media, a division of Verizon Communications, Inc., houses a trusted media ecosystem of premium brands like Yahoo, TechCrunch and HuffPost to help people stay informed and entertained, communicate and transact, while creating new ways for advertisers and media partners to connect. From XR experiences to advertising and content technology, Verizon Media is an incubator of innovation and is revolutionizing the next generation of content creation in a 5G world.For more information, contact Ned Desmond or visit